| JHX quote reference | $26.29 stock price at the July 31, 2026 close, cross-validated across sources | StockAnalysis, Macrotrends, and MarketBeat | August 3, 2026 |
| Market capitalization verification | $15.26 billion calculated from $26.29 x 580.34 million shares, with 0.00% variance versus the reported market cap | Pineify financial_rigor.py, Macrotrends, and MarketBeat | August 3, 2026 |
| Shares outstanding | 580.31 million to 580.34 million shares, up about 26% year over year after the AZEK cash-and-stock combination | StockAnalysis and MarketBeat key statistics | August 3, 2026 |
| FY2026 net sales | $4.8358 billion, up 24.7% year over year, cross-validated with 0.05% or less variance across sources | Company FY26 results summary and Macrotrends revenue history | August 3, 2026 |
| FY2026 net income and Q4 | GAAP net income $104.0 million for fiscal 2026 and $28.5 million for Q4, with GAAP EPS near $0.19 for the trailing twelve months | Company FY26 results summary, Macrotrends, and StockAnalysis | August 3, 2026 |
| FY2026 adjusted operating metrics | Adjusted EBITDA $1,265.8 million and adjusted diluted EPS $1.09 for fiscal 2026, with Q4 adjusted EBITDA $380.9 million and adjusted EPS $0.30 | Company FY26 results summary via TradingView SEC summary | August 3, 2026 |
| Cash flow and capex | FY26 operating cash flow $589.8 million and capital expenditures $383.9 million, with free cash flow still well below the $500 million-plus fiscal 2027 target | Company FY26 results summary and StockAnalysis cash flow | August 3, 2026 |
| Preliminary Q1 FY27 results | Consolidated net sales $1.449 billion to $1.475 billion versus guidance of $1.315 billion to $1.354 billion, EBITDA $399 million to $407 million, and GAAP net income $102 million to $104 million | James Hardie preliminary Q1 FY27 release via Business Wire and Motley Fool Australia | August 3, 2026 |
| FY2027 guidance | Net sales targeted at $5.25 to $5.41 billion, adjusted EBITDA at $1.45 to $1.50 billion, free cash flow above $500 million, and net leverage toward about 2.0x by end of Q2 FY28 | Company FY26 results and FY27 outlook summary | August 3, 2026 |
| Analyst targets | Average price target $30.54 with a Strong Buy consensus across 7 analysts on StockAnalysis, and $27.56 with a Moderate Buy consensus across 13 analysts on MarketBeat; recent raises include Oppenheimer to $32 and Stephens to $33 | StockAnalysis forecast and MarketBeat analyst consensus | August 3, 2026 |
| Debt and asbestos context | Total debt near $4.79 billion against about $269 million in cash, with net debt about $4.52 billion and Debt/EBITDA near 5x on a GAAP TTM basis, while asbestos liabilities remain material on the balance sheet | StockAnalysis balance sheet and company disclosures | August 3, 2026 |
| Valuation math | 24.1x fiscal 2026 adjusted EPS of $1.09 and roughly 21x forward adjusted EPS near $1.28, versus a triple-digit multiple on depressed GAAP EPS; three-scenario values near $15, $31, and $43 | Pineify financial_rigor.py valuation and three-scenario tools | August 3, 2026 |
| Technical range | 52-week range about $16.46 to $29.83, 50-day moving average near $24.56, 200-day moving average near $21.97, and RSI near 55.9 after the July rally | StockAnalysis, Macrotrends, and MarketBeat technical notes | August 3, 2026 |
| Short interest | About 19.44 million shares sold short, roughly 3.36% of shares outstanding, down about 2.67% month over month | StockAnalysis and MarketBeat short interest data | August 3, 2026 |